Yoder Theodore, Hirose Kyoko, Tsui Judith I, Feinberg Judith, Hagan Holly, Pho Mai T, Rowan Sarah E
University of Colorado School of Medicine, Aurora, Colorado, USA.
University of Chicago Medical Center, Chicago, Illinois, USA.
Open Forum Infect Dis. 2025 Apr 8;12(4):ofaf211. doi: 10.1093/ofid/ofaf211. eCollection 2025 Apr.
Innovative strategies are required to treat hepatitis C (HCV) among people who inject drugs (PWID). Integration of HCV treatment in syringe services programs (SSPs) may improve access, although multiple implementation challenges have been described.
We performed a scoping review of published models of HCV treatment integrated in SSPs in the United States.
We found 13 articles including randomized controlled trials, observational studies, cohort analyses, and qualitative analyses that described a variety of approaches to integration that produced significant improvements in treatment initiation and cure compared with a referral-based standard of care. Variations in delivery models (mobile unit vs brick-and-mortar sites), provider location (on-site vs telehealth), pretreatment evaluation, pharmacy access, supportive services (eg, peer navigation) and funding were described.
Expansion of these models in the United States would not only contribute to HCV elimination but also create opportunities for the provision of other key healthcare services to this important population.
需要创新策略来治疗注射吸毒者中的丙型肝炎(HCV)。将HCV治疗纳入注射器服务项目(SSP)可能会改善可及性,尽管已描述了多种实施挑战。
我们对美国已发表的将HCV治疗纳入SSP的模型进行了范围综述。
我们发现13篇文章,包括随机对照试验、观察性研究、队列分析和定性分析,这些文章描述了多种整合方法,与基于转诊的标准护理相比,这些方法在治疗启动和治愈方面有显著改善。描述了提供模式(移动单位与实体场所)、提供者位置(现场与远程医疗)、治疗前评估、药房服务、支持性服务(如同伴导航)和资金方面的差异。
在美国扩展这些模式不仅有助于消除HCV,还为向这一重要人群提供其他关键医疗服务创造了机会。